SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ganaxolone

LGND·Ligand Pharmaceuticals
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US (since 2022), EU (Immedica became MAH in June 2025), and China (approved 2024). No new approval decision is pending.
Why 3/10
No hard dated binary catalyst exists for ganaxolone in the next ~12 months from LGND's perspective. The drug is already approved and commercialized. Immedica's planned new Phase 3 study for IV ganaxolone (announced Oct 2026) targets a 2027 start, more than 12 months away, and Ligand's exposure is through Captisol supply, which is a very small component (Captisol revenue ~$8.7M total) of its diversified >200-asset portfolio.
Actionable Insight NEUTRAL

No near-term binary catalyst exists for ganaxolone affecting LGND. Immedica (private) plans to launch a new Phase 3 study of IV ganaxolone in refractory status epilepticus in 2027, but this is several years from any commercial outcome and Ligand's Captisol exposure is small. Watch Immedica's commercial execution for Ztalmy and any label expansions, but none are likely to move LGND stock materially.

Price Chart

Loading chart...

Executive Summary

Ganaxolone (brand name Ztalmy) is an FDA-approved neuroactive steroid for seizures in CDKL5 deficiency disorder (CDD), approved in March 2022. It was developed by Marinus Pharmaceuticals (MRNS), which was acquired by private Swedish rare-disease firm Immedica Pharma in February 2025 for $151M. The filing-hint ticker LGND (Ligand Pharmaceuticals) holds a Captisol formulation license and supply agreement for Captisol-enabled ganaxolone, but this is a minor revenue source within Ligand's diversified portfolio of over 200 royalty assets (total Captisol revenue ~$8.7M in 2026). Ganaxolone has no pending binary catalyst for LGND and represents a very small slice of Ligand's value.

How It Works

Ganaxolone is a synthetic version of a natural brain steroid. It works by boosting the activity of GABA, the brain's main calming/ inhibitory chemical signal. This reduces over-excitation that causes seizures. It is taken as an oral liquid suspension.

Trial Status

Ganaxolone was approved by the FDA in March 2022 for CDKL5 deficiency disorder (CDD) based on the positive Phase 3 Marigold trial. Two subsequent Phase 3 trials in other indications failed: the TrustTSC trial in tuberous sclerosis complex did not meet its primary endpoint (p=0.09, Oct 2024), and the RAISE trial in refractory status epilepticus met only one of two co-primary endpoints (June 2024). Immedica (the current owner) announced on Oct 26, 2026 it plans a new Phase 3 study of IV ganaxolone in refractory status epilepticus, to start in 2027.

The Two-Sided Case

▲ Bull Case4
Ztalmy is the only FDA-approved treatment for CDKL5 deficiency disorder, a rare pediatric epilepsy with no other approved therapies, giving it a strong market position
Three-year efficacy data presented at EEC 2026 showed sustained benefit in CDD patients, supporting long-term use
Label update in Dec 2025 with a 28-day titration schedule improved convenience for patients and prescribers
Immedica is investing in a new Phase 3 trial of IV ganaxolone for refractory status epilepticus, potentially expanding the addressable market
▼ Bear Case5
Phase 3 trials in tuberous sclerosis complex (TrustTSC) and refractory status epilepticus (RAISE) both failed or missed key endpoints, casting doubt on pipeline expansion beyond CDD
NCE-1 exclusivity expired in March 2026, opening the door to patent challenges (first eligible June 2026), though patents may protect until ~2042
Ztalmy's CDD indication targets an extremely small patient population, limiting peak revenue potential
For LGND specifically, ganaxolone-related Captisol revenue is minimal (~$8.7M total Captisol revenue in 2026, down 35.7% YoY) and immaterial to the company's $270M+ revenue base
The original developer Marinus was sold at a steep discount ($0.55/share, $151M) after clinical setbacks

Upcoming Catalysts

  • Immedica plans to initiate a new Phase 3 study of IV ganaxolone in refractory status epilepticus in 2027 (distant, not a near-term catalyst for LGND)
  • Continued commercial uptake of Ztalmy in CDD indication globally

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 fda.gov3 ir.marinuspharma.com4 ir.marinuspharma.com5 investor.ligand.com6 immedica.com7 news.cision.com8 drugs.com9 immedica.com10 investors.ovidrx.com11 ncegrid.springbiosolution.com12 immedicaus.com